Ozdemir Ferda, Rodoplu Meliha
Department of Physical Medicine and Rehabilitation, Trakya University School of Medicine, Edirne, Turkey.
Chin Med J (Engl). 2005 Mar 5;118(5):383-90.
Alendronate, a nitrogen-containing bisphosphonate is a specific inhibitor of bone resorption and now in the forefront of treatment of osteoporosis. In this study, we reported a significant increase in bone mineral density (BMD) of the spine and the hip in postmenopausal women taking alendronate at 10 mg/d for 1, 2 and 3 years.
Participants had received daily, oral, 10 mg dose of alendronate for one to three years and placed into one of three groups according to alendronate treatment duration: 41 women received alendronate for 1 year (group I), 46 received alendronate for 2 years (group II), and 30 received alendronate for 3 years (group III). Measurements of bone density had been made by dual energy X-ray absorbtiometry once each year.
The differences in L2-L4, L2, L4, femoral neck and trochanter BMD values before and after treatment for first group were significantly different. In second group, significant differences between initial and after treatment were found at the other sites except at the Ward's triangle. In the third group, only a significant increase in the L2-L4, L2, L3, L4, trochanter BMD values between before treatment and at the end of third year was found. Comparisons between groups were performed with Student's t test. ANOVA was used to test the age, menopause age, menopause duration and initial BMD values between the three groups. Calculated P values of less than 0.05 were considered statistically significant.
Alendronate had increased BMD significantly at the spine and hip in postmenopausal women over three years. Increases of BMD in third group were significant during the first and second years. However, continued therapy with alendronate had been required to maintain the gain in BMD over the third year.
阿仑膦酸钠是一种含氮双膦酸盐，是骨吸收的特异性抑制剂，目前处于骨质疏松症治疗的前沿。在本研究中，我们报告了绝经后女性服用10mg/d阿仑膦酸钠1年、2年和3年后，脊柱和髋部的骨矿物质密度（BMD）显著增加。
参与者每天口服10mg剂量的阿仑膦酸钠，持续1至3年，并根据阿仑膦酸钠治疗持续时间分为三组：41名女性接受阿仑膦酸钠治疗1年（第一组），46名接受阿仑膦酸钠治疗2年（第二组），30名接受阿仑膦酸钠治疗3年（第三组）。每年通过双能X线吸收法进行一次骨密度测量。
第一组治疗前后L2-L4、L2、L4、股骨颈和大转子的骨密度值差异有统计学意义。第二组除沃德三角外，其他部位治疗前后差异有统计学意义。第三组仅发现治疗前与第三年末L2-L4、L2、L3、L4、大转子的骨密度值显著增加。组间比较采用Student t检验。采用方差分析检验三组间的年龄、绝经年龄、绝经持续时间和初始骨密度值。计算出的P值小于0.05被认为具有统计学意义。
阿仑膦酸钠在三年时间里显著增加了绝经后女性脊柱和髋部的骨密度。第三组在第一年和第二年骨密度增加显著。然而，需要持续使用阿仑膦酸钠治疗以维持第三年骨密度的增加。
